Revance Q3 2022 Earnings Report
Key Takeaways
Revance Therapeutics reported strong Q3 2022 financial results, highlighted by FDA approval of DAXXIFY™ and a 47% year-over-year increase in total revenue. The company also completed a $230 million follow-on offering, strengthening its financial position.
Received FDA approval for DAXXIFY™ for injection for the treatment of glabellar lines.
Q3 total revenue reached $29.0 million, a 47% increase year-over-year.
RHA® Collection revenue grew to $26.1 million, a 43% increase year-over-year.
Aesthetic accounts across products and services exceeded 4,500 at quarter-end.
Revance
Revance
Forward Guidance
Revance expects its 2022 GAAP and non-GAAP operating expenses to be on the upper end of its previously announced guidance ranges of $375 million to $400 million and $260 million to $280 million, respectively. Management projects that the company’s U.S. aesthetics portfolio (DAXXIFY™, RHA® Collection, OPUL®) will be funded to cash flow breakeven.